← Leaderboards
So-Youn Kim
University Of Nebraska Medical Center
$2,229,425
Attributed
$2,857,981
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $629.4K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,857,981 · 2
By mechanism
R01$2,857,981 · 2
Top collaborators
- Shuo Xiao2 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Shyamal K Roy$7,237,756
- Cheng Wang$7,992,551
- Ricia Katherine Hyde$2,818,181
- Kendra L Clark$190,967
Others in their field
Other Emerging Leaders on “Ovarian Reserve”
- David Pepin · Massachusetts General Hospital$2,535,692
- Ewelina M Bolcun-Filas · Jackson Laboratory$2,085,332
- Catherine Racowsky · Brigham And Women'S Hospital$2,065,087
- Amanda Nicole Kallen · University Of Vermont & St Agric College$1,788,519
- Jorge Eduardo Chavarro · Harvard School Of Public Health$1,784,218
- Helen McNeill · Washington University$1,707,951
Research focus
Ovarian ReservePrimordial FollicleGerm CellsOvarianPrimary Ovarian InsufficiencyFertilityChemotherapeutic AgentCessation Of LifeLeukemiaOocytesOvaryPathway InteractionsFemaleCancer PatientApoptosisCell TypeCancer TherapyApoptoticChemotherapyInfertilityDna DamageMouse ModelEndocrineSide Effect
Grant awards (7)
Oogenic JNK in gonadotoxic chemotherapy-induced primary ovarian insufficiency$629,384
R01 · FY2025 · HD
Oogenic JNK in gonadotoxic chemotherapy-induced primary ovarian insufficiency$627,728
R01 · FY2024 · HD
Development of mechanism-based ovarian reserve protecting adjuvant therapies against gonadotoxic therapeutic agents$317,581
R01 · FY2023 · HD · contact PI
Development of mechanism-based ovarian reserve protecting adjuvant therapies against gonadotoxic therapeutic agents$317,581
R01 · FY2022 · HD · contact PI
Development of mechanism-based ovarian reserve protecting adjuvant therapies against gonadotoxic therapeutic agents$317,581
R01 · FY2021 · HD · contact PI
Development of mechanism-based ovarian reserve protecting adjuvant therapies against gonadotoxic therapeutic agents$324,063
R01 · FY2020 · HD · contact PI
Development of mechanism-based ovarian reserve protecting adjuvant therapies against gonadotoxic therapeutic agents$324,063
R01 · FY2019 · HD · contact PI